Long-term surveillance study of rituximab originator treated patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)
Lay Summary: What does this mean for patients? Rituximab is used to treat active disease and to prevent relapses in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). Serious complications, including infections, low natural antibody levels, cancers, low white blood cell levels, heart...
Autors principals: | Uchida, L, Jones, RB, Smith, RM, Nodale, M, Bond, S, Loechel, C, King, M, Luqmani, R, Gray, D, Barrett, J, Jayne, DRW |
---|---|
Format: | Journal article |
Idioma: | English |
Publicat: |
Oxford University Press
2024
|
Ítems similars
-
Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis
per: Shah S, et al.
Publicat: (2015-08-01) -
Echocardiogram: The GPS to GPA’s Heart (Granulomatosis with Polyangiitis)
per: Manpreet K. Parmar, et al.
Publicat: (2019-01-01) -
Molecular targeted therapies for microscopic polyangiitis and granulomatosis with polyangiitis
per: Masayoshi Harigai, et al.
Publicat: (2019-05-01) -
An Unusual Presentation of Granulomatosis with Polyangiitis (GPA): Case Report
per: Sabrina Khuder, et al.
Publicat: (2023-12-01) -
Tension Pneumothorax as Initial Manifestation of Granulomatosis with Polyangiitis (GPA)
per: Rúben Reis, et al.
Publicat: (2021-02-01)